Regulatory & Legal

A major patent deal shields Esperion's flagship drugs from generics, securing future revenue but delaying cheaper options for millions of patients.

A partnership between NSA Labs and Proscia is slashing study times for brain research, showing how digital platforms are key to finding new therapies faster.

With a new rotator cuff device and enhanced meniscal repair system, Arcuro Medical is challenging orthopedic giants with its innovative all-suture technology.

With its new SOC 2 Type 2 certification, Tech Foundry aims to set a new standard for secure, high-touch software development for SaaS enterprises.

ASCU pays millions to end its partnership with a Rio Tinto venture, betting it can develop the massive Cactus copper project in Arizona all on its own.

Cyrano Therapeutics' CYR-064 shows promise in a Phase 2 study, potentially becoming the first approved drug for persistent post-viral smell loss.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

A new report reveals chronic underfunding and human error leave U.S. public services dangerously exposed to relentless ransomware and phishing attacks.

A new supply agreement for the rare isotope Actinium-225 between NorthStar and BIOEMTECH promises to break a critical bottleneck in radiopharmaceutical R&D.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

A new series from A3 and BBC StoryWorks moves beyond efficiency to show how automation is augmenting human lives in healthcare, education, and more.

Landmark study in JAMA Neurology shows BRIUMVI offers near-zero relapse rates and stable disability, reshaping long-term multiple sclerosis treatment.

Lufax names Xiang Ji as its new CEO amid major financial struggles. The move signals a tighter grip from controlling shareholder Ping An Group.

A new program in Michigan uses AI to analyze existing CT scans, detecting silent heart risks and connecting patients to care before symptoms even appear.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

With a new regulatory chief, Ray Therapeutics accelerates its mission to bring its goggle-free optogenetic therapies for blindness through clinical trials.

Profitable and with little debt, this holding company is leveraging a diverse portfolio as it prepares for a major stock market uplist. Here's a closer look.

Prestigious toxicology awards recognize UL Research Institutes' vital work on vaping health risks and innovative methods for assessing chemical safety.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

With 23,000 metres of drilling, Copper Giant aims to unlock one of the world's largest undeveloped copper caches, vital for the energy transition.